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Abstract
There is now a large body of evidence linking inflammation to Alzheimer's disease (AD). This
association manifests itself neuropathologically in the presence of activated microglia and
astrocytes around neuritic plaques and increased levels of inflammatory mediators in the brains of
AD patients. It is considered that amyloid-β peptide (Aβ), which is derived from the processing of
the longer amyloid precursor protein (APP), could be the most important stimulator of this
response, and therefore determining the role of the different secretases involved in its generation
is essential for a better understanding of the regulation of inflammation in AD. The finding that
certain non-steroidal anti-inflammatory drugs (NSAIDs) can affect the processing of APP by
inhibiting  β- and γ-secretases, together with recent revelations that these enzymes may be
regulated by inflammation, suggest that they could be an interesting target for anti-inflammatory
drugs. In this review we will discuss some of these issues and the role of the secretases in
inflammation, independent of their effect on Aβ formation.
Introduction
Alzheimer's disease (AD) is a devastating neurological dis-
ease affecting more than 26 million people around the
world, and there are indications that this number will
quadruple by 2050. Age is the most significant risk factor
and it is estimated that 50% of people over 85 have either
AD or Mild Cognitive Impairment (MCI). Brains of indi-
viduals with AD manifest massive neuronal and synaptic
loss in certain areas which result in the memory impair-
ment and disorientation associated with this disease. The
neuroanatomical study of a typical AD brain reveals the
presence of two characteristic lesions: extracellular amy-
loid (or senile plaques) and intracellular neurofibrillary
tangles composed primarily of hyperphosphorylated tau
protein [1]. Amyloid plaques contain small amyloid-β
peptides (Aβ), which are toxic products from the catalytic
cleavage of a larger amyloid precursor protein (APP) [1,2].
In 1907 Alois Alzheimer described unique structures in the
cerebral cortex of a 55 year old woman with progressive
dementia that are now referred to as senile plaques [3].
Histological methods used to demonstrate plaques
including thioflavine S, various silver stains, and immu-
nocytochemical stains reveal various biochemical compo-
nents of plaques. Aβ has been reported to have
heterogeneous carboxyl termini, and Aβ1–40 and Aβ1–42
appear to be the major species in the parenchymal depos-
its. It is this C-terminal variation that has been most often
associated with pathogenicity, with Aβ1–42 found to be
the most toxic form [1,2]. Aβ is found in normal cerebro-
spinal fluid and in conditioned media from various tissue
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culture cell lines [4-6], suggesting that it is produced and
secreted constitutively.
Aβ deposition is considered a major pathogenic step in
the development of AD. Evidence supporting the amyloid
hypothesis has been extensively reviewed [7]. On the
other hand, there is also the view that Aβ plaque forma-
tion is an epiphenomenon and its pathophysiological
functions still remain unclear. In this regard, it has been
shown that in people with AD the density of Aβ plaques
correlates poorly with the severity of dementia [8]. There
are, however, indications that dendritic and synaptic
injury occur early in the course of the disease and that pro-
tofibrils and oligomers of Aβ40 and Aβ42 could cause
neuronal dysfunction [9]. In addition, a recent study car-
ried out using multiphoton laser confocal microscopy
showed that in the early stages of the disease, micro-
plaques can damage neighbouring axons and dendrites
within days [10]. Furthermore, intraneuronal Aβ has also
been implicated in the onset of cognitive dysfunction
[11].
APP is a type I integral membrane protein [12] that resem-
bles a signal-transduction receptor. It is synthesized in the
ER, post-transcriptionally modified in the Golgi (includ-
ing N- and O-linked glycosylation, sulfation and phos-
phorylation), and transported to the cell surface via the
secretory pathway. APP is also endocytosed from the cell
surface and processed in the endosomal-lysosomal path-
way [13,14], although autophagic vacuoles may also be a
site for Aβ production [15]. Alternative processing path-
ways of APP have been described (Figure 1).
Proteolysis of APP by α-secretase or β-secretase leads to
the secretion of soluble α-APPs or β-APPs. This generates
C-terminal fragments of 10 kDa and 12 kDa respectively,
which are inserted in the membrane. These fragments can
be cut by γ-secretase to release the peptides P3 and Aβ [16]
and a cytoplasmic fragment identified as AICD (APP intra-
cellular domain) [17]. Intriguingly, AICD starts at posi-
tion 49/50 and would not correspond to the end of Aβ
variants Aβ40 and Aβ42. Therefore this cleavage site,
termed ε-cleavage, is topologically highly similar to the S3
cleavage of Notch [17,18]. Recently, a new cleavage site
was described for γ-secretase. The ξ-cleavage occurs
between ε- and γ-cleavage sites and generates longer Aβ
forms within cells and in the brain, including Aβ43, Aβ45,
Aβ46, and Aβ48 [19,20].
Inflammation and Alzheimer's disease
There is strong evidence that Aβ toxicity could be medi-
ated through the induction of inflammatory events in the
brain. Over the past decade it has been speculated that the
inflammatory response associated with the presence of
neuritic plaques could be involved in neuronal damage
and contribute to the progression of the disease [21,22]. A
common feature in the brain of AD patients is the pres-
ence of astrocytes and microglia surrounding the senile
amyloid plaques, already described by Alois Alzheimer in
1907.
The first evidence for an excessive inflammatory process in
AD came from a study carried out in AD and Down syn-
drome brains that showed increased levels of S100 and IL-
1 [23]. Since then, many of the cytokines and chemokines
that have been studied in AD, including IL-1β, IL-6, TNF-
α, IL-8, TGF-β and macrophage inflammatory protein-1α
(MIP-1α) have been found to have altered expression
compared with control individuals [22]. Animal models
of Alzheimer's disease, such as the APP transgenic line
Tg2567 carrying the Swedish mutation, also show
enhanced levels for TNF-α, IL-1β, IL-1α, chemoattractant
protein-1, COX-2 and complement component 1q
[24,25]. In addition, an increased risk of AD has been
associated with several polymorphisms of proinflamma-
tory genes, including IL-1 [26], IL-6 [27], TNF-α [28], and
α1-antichymotrypsin [29].
Clinical investigation and studies in AD animal models
have reinforced the suggestion that inflammatory changes
in the AD brain are an early and prominent feature. In
support of this hypothesis, imaging studies have detected
microglial activation in patients at very early clinical
Proteolytic processing of APP Figure 1
Proteolytic processing of APP. Proteolysis of APP by α-
secretase or β-secretase leads to the secretion of αAPPs or 
βAPPs. Both secretases generate C-terminal fragments 
(CTF) of 10 kDa and 12 kDa respectively, which are inserted 
in the membrane (grey). These fragments can be cut by γ-
secretase to release the peptides P3 and Aβ. Two further 
cleavage sites, termed ε and ζ, have been identified in the 
CTF.
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stages of the disease [30]. Moreover, a recent study inves-
tigating predictors in plasma from MCI patients and those
with pre-symptomatic AD that converted to AD identified
factors associated with inflammation, such as TNFα, IL-3
IL-1α and IL-11 [31]. In animal models of AD, focal glial
activation already takes place before amyloid plaque for-
mation in APPV717 transgenic mice at 3 months of age
[32]. These animals showed decreased LTP already at this
age, which could be caused by impaired neuronal func-
tion derived from the increased secretion of pro-inflam-
matory cytokines [33]. Prominent microglial activation
also preceded tangle formation in 3 month old P301S Tg
mice [34]. Interestingly, neuroinflammation has been
proposed to be the link between Aβ deposition and the
formation of neurofibrillary tangles. Products of inflam-
mation, such as pro-inflammatory cytokines might
change the substrate specificity of kinases/phosphatases
leading to tau phosphorylation at pathological sites [35].
Further evidence for a link between inflammation and AD
comes from observations in head-injured patients. A
number of large epidemiological studies (e.g. the MIRAGE
study) [36] have identified an increased risk of dementia
in patients who have suffered a serious head injury during
their life. At the more acute pathological level, in a cohort
of patients who died within weeks of their head injury,
approximately a third showed signs of Aβ deposition in
their brains [37]. While there was a wide age range in this
cohort and some of these Aβ deposits were almost certain
to predate the trauma, the deposits seen in the younger
cases are likely to have been generated de novo, as a result
of the trauma. We have hypothesised that it is the inflam-
matory response generated as a result of the trauma which
triggers the AD-type degenerative changes [38]. Traumatic
brain injury in rats has been shown to increase BACE1
activity in the hippocampus with a concomitant increase
in APP cleavage products [39]. Work in a porcine model
of head injury has shown accumulation of APP and BACE
in injured axons and it is suggested that the abnormal
accumulation of these proteins may favour Aβ production
[40]. At the molecular level acute hypoxia has been shown
to increase the production of APP and subsequently Aβ.
This action is thought to be mediated by the binding of
HIF-1 to the promoter region of BACE1 mRNA resulting
in increased levels of BACE1 protein in the tissue [41].
More recently it has been shown that brain injury in mice
increases the expression of presenilin 1 and nicastrin,
both components of the γ-secretase complex, in activated
microglia and astrocytes [42].
Conversely, it has to be noted that inflammation is not
only contributing to the disease progression, but could
have beneficial effects. This may depend on the inflamma-
tory elements activated, the time in the disease develop-
ment and also whether the response is acute or chronic.
Activated microglia can reduce Aβ accumulation by
increasing its phagocytosis or extracellular degradation
[43-45]. Microglia also release trophic factors such as the
glia-derived neurotrophic factor (GDNF), which is neuro-
protective [46]. In addition, certain cytokines have an
anti-inflammatory effect, such as IL-1 receptor antagonist
(IL-1Ra), IL-4, IL-10 and TGF-β [22,47]. It was recently
reported that the interaction between newly formed amy-
loid plaque and microglia shows that, unless further acti-
vated, microglia do not successfully clear plaques but may
well restrict their growth, leading to a steady state of
plaque size after initial formation [10].
Further support for the involvement of inflammation
with the pathogenesis of AD came from the finding in epi-
demiological studies that treatment with non-steroidal
anti-inflammatory drugs (NSAIDs) was associated with a
reduced risk of developing AD. A meta-analysis of nine
studies revealed that the benefit was greater with long-
term use than with intermediate use [48]. Recently, a
modified Mini-Mental State Examination reported that
NSAIDs use prevented cognitive decline in older adults if
started in midlife (prior to age 65) rather than late in life
(after age 65). This effect was more pronounced in those
who had one or more APOE e4 alleles [49]. However, the
possible preventive effect of NSAIDs has not been yet con-
firmed in clinical trials. The failure of the trials may be
attributed to the facts that the benefit of NSAIDs may only
be observed in early phases of the disease, that is, they are
preventive and not curative, and also to the choice of
NSAID, mostly COX-2-specific inhibitors because (i) only
a subset of NSAIDs are able to lower Aβ production and
(ii) this capacity appears to be COX-2 independent [50].
In animals, the beneficial effects of NSAIDs have been
confirmed, showing behavioural improvement and
reductions in glial activation, in Aβ levels and plaque size
[45,51-55]. In vitro studies have revealed several potential
targets for NSAIDs, including NFκB, Rho-GTPases, PPARγ
and secretases [50]. However, the inhibition of the canon-
ical targets of NSAIDs, cyclooxygenase-1 and -2 (COX-1
and COX-2), do not seem to be responsible for the protec-
tive effect of NSAIDs in AD. On the contrary, COX-2
inhibitors may raise Aβ1–42 secretion [56].
The finding that NSAIDs could affect APP processing and
that certain NSAIDs can inhibit β and γ-secretases with the
recent revelation that secretases may be influenced by
inflammation indicates that they could be an interesting
target for anti-inflammatory drugs [50].
Secretases and inflammation
α-Secretase
APP is cleaved by α-secretase in the centre of the Aβ
domain. Three related metalloproteases of the ADAM (a
disintegrin and metalloprotease) family, ADAM-9,Journal of Neuroinflammation 2008, 5:25 http://www.jneuroinflammation.com/content/5/1/25
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ADAM-10 and ADAM-17, also termed TACE (tumor
necrosis factor converting enzyme), appear to exert α-
secretase activity [16,57]. A confirmation that ADAM10 is
involved in α-secretase activity came from studies in trans-
genic mice. A moderate neuronal over-expression of
ADAM10 in mice transgenic for human APP([V717I])
showed increased secretion of the neurotrophic soluble α-
secretase-released N-terminal APP domain (α-APPs),
reduced formation of Aβ peptides, and prevention of their
deposition in plaques [58]. Functionally, in these mice
impaired long-term potentiation and cognitive deficits
were alleviated. Expression of mutant catalytically inactive
ADAM10 led to an enhancement of the number and size
of amyloid plaques in the brains of double-transgenic
mice. These results provided the first in vivo evidence for a
proteinase of the ADAM family as an α-secretase of APP,
revealed activation of ADAM10 as a promising therapeu-
tic target, and supported the hypothesis that a decrease in
α-secretase activity contributes to the development of AD
[58]. Another candidate with α-secretase activity is
BACE2, which likewise cleaves within the Aβ domain and
abrogates Aβ formation [57] (Figure 1).
ADAM proteinases have emerged as the major protein
family that mediates ectodomain shedding, the proteo-
lytic release of extracellular domains from their mem-
brane-bound precursors. Proteolytic cleavage or
ectodomain shedding is an additional mechanism
whereby cells can regulate the proteins expressed on their
cell surface. In many cases, soluble ectodomains are bio-
logically active as mediators of functions ascribed to their
transmembrane counterparts [59]. ADAM-like sheddases
activate, for instance, growth factors and cytokines, thus
regulating signalling pathways that are important in
development and pathological processes such as cancer
[60]. ADAM17 and 10 appear to play a particularly prom-
inent role in ectodomain shedding of inflammatory pro-
teins at all stages of leukocyte recruitment. Soluble TNF-α
is released from its membrane-bound precursor by shed-
ding through ADAM17 [61]. In vivo studies have shown
that many, but not all, of the inflammatory effects of TNF-
α require cleavage and shedding from the cell surface.
Besides TNF-α, ADAM17 cleaves ectodomains of other
receptors and ligands, such as TNFR2 and L-selectin [62].
In addition, it was recently shown that IL-1R2 can be pro-
teolytically processed in a manner similar to APP [63]. IL-
1R2 undergoes ectodomain shedding in an α-secretase
manner, resulting in the secretion of the IL-1R2 ectodo-
main and the generation of a C-terminal fragment.
That α-secretase is involved in inflammation is supported
by the observation that ADAM-10 is expressed constitu-
tively by astrocytes in the normal and inflamed human
CNS [64]. ADAM10 and ADAM-17 are also enriched in
microglia [65]. The functions of ADAMs in microglia are
complex and they do not only have pro-inflammatory
and neurotoxic properties but also reparative ones [66]. In
fact, IL-1α has been reported to increase ADAM-17 and
ADAM-10 levels and α-secretase activity in human astro-
cytic cultures [67]. More recently, it has been shown that
the proinflammatory cytokines TNF-α, IFN-γ and IL-1β, as
well as TGF-β and LPS, are able to increase ADAM10 activ-
ity, leading to a loss in E-cadherin expression, which is
another substrate for this secretase [68].
On the other hand, it has been also reported that various
NSAIDs (including nimesulide, ibuprofen and indometh-
acin) stimulate the non-amyloidogenic secretion of
sAPPα from neuroblastoma cells [69]. Shedding of sAPPα
induced by nimesulide and thalidomide was modulated
by inhibitors of PKV and Erk MAPK, indicating that
NSAIDs activate the Erk MAPK signalling cascade. How-
ever, these results have not been reproduced by other
groups [70,71].
β-Secretase
β-Secretase (BACE1 for β-site APP cleaving enzyme) was
cloned and identified as a type I transmembrane aspartyl
protease [72]. BACE1 cleaves APP at the N-terminal posi-
tion of Aβ. BACE1 deficiency precludes Aβ formation in
transgenic mice, and does not cause or promote any neu-
rological or phenotypic abnormalities. However, it has
been recently demonstrated that BACE1 knockout mice
exhibit a number of schizophrenia-like behavioural traits,
most likely because BACE1 is involved in the cleavage of
neuregulin-1, which has been linked to the pathogenesis
of schizophrenia and related psychiatric disorders [73].
Because BACE1 inactivation rescues memory deficits in
transgenic mice [74], this strongly supports the impor-
tance of BACE1 as a therapeutic target in AD.
BACE1 is primarily expressed in neurons [72,75,76], but
it can be also expressed in astrocytes under conditions of
chronic stress [77] and in old transgenic mice [76,32]. In
addition, in young transgenic mice, neuronal BACE1 was
induced in the proximity of activated microglia and astro-
cytes [32]. These observations lead to the conclusion that
BACE1 expression is regulated by inflammatory events.
BACE1 has also been found up-regulated in neuronal cul-
tures upon exposure to pro-inflammatory cytokines
[70,78], under oxidative stress in NT2 neurons [79], and
in the hippocampus of rats after experimental traumatic
brain injury [39]. In addition, BACE1 protein levels, activ-
ity and the β-secretase product (β-CTF) are increased in
brain of sporadic AD patients [80,81] as well as in plate-
lets and CSF from AD and MCI patients [82-84]. These
alterations in BACE1 expression and activity indicate a
transcriptional and/or translational regulation of BACE1
expression in the brain [85]. Interestingly, consensus
binding sites for various transcription factors that areJournal of Neuroinflammation 2008, 5:25 http://www.jneuroinflammation.com/content/5/1/25
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known to be regulated by inflammation (such as NFκB,
PPARγ and STAT1) are present in the BACE1 promoter.
Transcriptional regulation
NFκB
NFκB sites are present in the promoters of APP [86], prese-
nilin and BACE1 [87]. In neurons exposed to soluble Aβ
peptides and in TNFα-activated glial cells the mutation of
the BACE1 promoter NFκB site led to significant decreases
in promoter activity, indicating an activating role for
NFκB in BACE1 expression in Aβ [87]. In addition, some
NSAIDs such as flurbiprofen and indomethacin, which
target NFκB, have been shown to be effective at decreasing
amyloid load in vitro and also in APP transgenic mice
[54,55,88]. A recent report showed that deletion of TNFα1
death receptor (TNFα1R) in APP23 transgenic mice inhib-
ited Aβ generation reducing BACE1 levels and activity via
the NFκB pathway [89].
The effect of NFκB on BACE1 promoter could be direct or
through changes in PPARγ, because PPARγ agonists can
antagonize the activity of transcription factors such as
NFκB [50].
PPARγ
PPARγ is a transcription factor that is involved in the reg-
ulation of the metabolism of glucose and lipids, in cellu-
lar differentiation as well as in the control of transcription
of a wide range of inflammatory genes. A consensus bind-
ing site for PPARγ was found in the BACE1 promoter.
PPARγ activation by agonists such as thiazolidinediones
(TZD) and certain NSAIDs such as ibuprofen, indometh-
acin and naproxen results in a decrease of BACE1 tran-
scription, expression and activity [70]. Furthermore, lack
of PPARγ led to an increase of BACE1 promoter activity
[90], which suggested that PPARγ could be a repressor of
BACE1.
PPARγ levels are decreased in AD brain, indicating that
inflammatory events may decrease PPARγ transcription.
Furthermore, in vitro experiments have shown that inflam-
matory cytokines and oxidative stress decrease PPARγ lev-
els. Therefore, these findings suggest the existence of a
down-regulation of PPARγ under inflammatory condi-
tions, which would result in an increase in BACE1 tran-
scription and Aβ generation. This effect could be
prevented by modulation of PPARγ activity by NSAIDs,
which have been shown to increase the levels of PPARγ in
adipocytes and neurons [90,53].
STAT-1
STAT-1 can bind directly to a putative STAT1 binding
sequence in the BACE1 promoter. A recent study showed
that when STAT1 becomes phosphorylated by IFNγ-medi-
ated activation of JAK2 and ERK1/2, STAT1 binds to
BACE1 promoter region to increase BACE1 protein
expression in astrocytes [91]. On the other hand, another
report has demonstrated that IFNγ-receptor knockout
mice crossed with Tg2576 mice expressing the human
Swedish mutant APP had reduced gliosis and amyloid
plaque compared with Tg2756 animals, apparently by
decreasing TNFα secretion and the number of reactive
astrocytes expressing BACE1 in cortex and hippocampus
[78].
Post-transcriptional modifications
Evidence has been presented for regulation of BACE1
expression at the translational level. The untranslated 5'-
BACE1 transcript leader contains upstream open reading
frames (uORF) that can reduce the translation of the main
open reading frame [92,93]. It remains unclear as to
whether BACE1 translation is constitutively repressed or
whether the repression may be alleviated upon physiolog-
ical and pathophysiological stimuli [85]. Potentially, the
identification of proteins specifically binding to long, GC-
rich 5'UTR may yield new insights into the possible regu-
lation of BACE1 translation. Evidence for these mecha-
nisms was shown by Zacchetti et al., who described that
the 5'-UTR-dependent translational repression of BACE1
may be alleviated in activated astrocytes [94]. Therefore, it
seems that inflammation may play also a role in the trans-
lational regulation of BACE1.
γ-Secretase
γ-Secretase is a protein complex of four essential mem-
brane proteins called aph-1, pen-2, nicastrin and preseni-
lin (PS). While aph-1, pen-2 and nicastrin function in the
assembly and subcellular transport of γ-secretase and in
the recognition of protein substrates [95-97]. PS proteins
are members of an aspartyl protease family and represent
the catalytically active components of the γ-secretase com-
plex [98]. PS1 and PS2 proteins are homologous poly-
topic membrane proteins critically involved in intra-
membraneous cleavage of APP and a number of other
type I membrane proteins [98-100]. Accordingly, PS pro-
teins have been implicated in different biological proc-
esses, including the regulation of cell differentiation and
death, calcium homeostasis, cell adhesion, and subcellu-
lar trafficking of several membrane proteins. Mutations in
PS are associated with familial forms of early onset Alzhe-
imer's disease (AD) and increase the ratio of Aβ42/Aβ40
by either elevating production of the elongated, highly
fibrillogenic Aβ42 or by decreasing the generation of
Aβ40 [57,101,102].
γ-Secretase and inflammation
It was recently published that activated microglia and
astrocytes have enhanced expression of PS and nicastrin
following brain damage [42]. Although glial cells express
PS1, it is not known if PS1 mutations alter glial cell func-Journal of Neuroinflammation 2008, 5:25 http://www.jneuroinflammation.com/content/5/1/25
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tions. Carriers of PS FAD associated mutations not only
show earlier deposition of Aβ in β-amyloid plaques, but
also inflammatory processes in the brain [90]. On the
other hand, it is unclear whether PS FAD associated muta-
tions cause neuroinflammation by promoting formation
and deposition of Aβ42 or by triggering other processes.
In PS1 associated FAD brain, distinct 'inflammatory
plaques' have been described, that lack reactivity for apol-
ipoprotein E and Aβ in the core, but revealed association
with reactive microglia and astrocytes, suggesting that
mutations in PS1 could also induce Aβ independent neu-
roinflammation in Early Onset Alzheimer's disease
(EOAD) [103]. In addition, studies using knock-in mice
for PS1 FAD mutations have revealed an enhanced
inflammatory cytokine response to immune challenge
with bacterial lipopolysaccharide (LPS). LPS-induced lev-
els of mRNAs encoding TNFα, IL-1α, IL-1β, IL-1 receptor
antagonist, and IL-6 were significantly greater in the hip-
pocampus and cerebral cortex of PS1 mutant mice as com-
pared to wild-type mice. These findings demonstrate an
adverse effect of PS1 mutations on microglial cells that
results in their hyperactivation under pro-inflammatory
conditions, which may, together with direct effects of
mutant PS1 in neurons, contribute to the neurodegenera-
tive process in AD [104].
Additional evidence for an Aβ independent role of PS pro-
teins in inflammation comes from studies with condi-
tional knockout mice lacking both PS genes in the
postnatal forebrain. These mice display strong age-
dependent neurodegeneration and impairment of cogni-
tive function [105]. Gene profiling revealed up-regulation
of several pro-inflammatory genes, including glial fibril-
lary acidic protein, complement component C1q, and
cathepsin S. Also, activated microglia were detected in the
brain of these mice. Since Aβ production is strongly
reduced upon deletion of PS in forebrain neurons, these
data indicate that impairment of PS function could also
trigger inflammation independent of Aβ [105]. Analo-
gously, the cleavage of other substrates for PS, such as
Notch, could also have some effect on brain inflamma-
tion. It was shown that mice transgenic for antisense
Notch and normal mice treated with inhibitors of γ-secre-
tase showed reduced damage to brain cells and improved
functional outcome in a model of focal ischemic stroke.
These mice had a reduced number of activated microglial
cells in the brain after ischemic perfusion [106].
NSAIDs and γ-secretase
As described above several NSAIDs decrease the risk for
development of AD. Although the molecular mecha-
nism(s) underlying this protective activity remain to be
identified, certain NSAID could directly modulate γ-secre-
tase activity [107]. Thus, besides suppression of inflam-
matory processes via inhibition of COX dependent
biosynthesis of pro-inflammatory prostaglandins, the
protective role of NSAIDs could also involve altered gen-
eration of Aβ. Indeed, several NSAIDs, including ibupro-
fen, sulindac sulphide, and indomethacin could decrease
the levels of secreted Aβ42 [108,54,109]. Importantly,
generation of Aβ40 is largely unaltered by these com-
pounds, indicating that certain NSAIDs modulate rather
than inhibit γ-secretase activity. The decrease in Aβ42 pro-
duction was associated with increased generation of Aβ38
suggesting a shift in the cleavage specificity of the protease
[107]. However, more recently it has been shown that the
generation of Aβ38 and Aβ42 is independent and differ-
ently affected by FAD mutations in PS as well as by mod-
ulators of γ-secretase [110]. After the initial identification
of ibuprofen, sulindac sulphide, and indomethacin as
selective Aβ42 lowering drugs, several other NSAIDs,
including flurbiprofen and fenoprofen have been shown
to exert similar effects [54]. Because Aβ42 lowering activ-
ity was also observed with several derivatives of NSAIDs
that do not inhibit COX, and was also present in COX1/2
deficient cell lines, the modulation of γ-secretase activity
is unlikely to be mediated via COX enzymes [107].
Surprisingly, the PPARα antagonist fenofibrate and some
COX-2 specific inhibitors could even increase Aβ42 pro-
duction [56,111,112]. Whether additional effects of
NSAIDs on NFκB and PPARα or PPARγ (see above) con-
tribute to the Aβ42 lowering activity remains to be inves-
tigated in more detail. However, certain NSAIDs decrease
Aβ42 production in vitro with purified γ-secretase com-
plex, indicating NFκB and PPARγ independent effects
[113,114]. Interestingly, FAD associated mutations in PS1
could cause insensitivity of γ-secretase to Aβ42 lowering
NSAIDs [115]. Because direct interaction of NSAIDs with
the presenilins or other components of the γ-secretase
complex has not been shown so far, the molecular mech-
anisms for the action of NSAIDs are unclear. Since
NSAIDs reveal Aβ42 lowering activity at relatively high
doses (IC50 values of 25 – 500 μM) at which they could
also affect biophysical properties of biological mem-
branes, the modulation of γ-secretase specificity might
also involve interference with membrane fluidity and/or
accessibility of substrate to the enzyme [116]. Nonethe-
less, since NSAIDs, even at higher concentrations did not
inhibit cleavage of Notch and ErbB4 or alter AICD forma-
tion, this class of inhibitors might be valuable com-
pounds to selectively decrease Aβ42 production without
affecting important intracellular signaling pathways,
thereby reducing potential side effects in clinical applica-
tions.
In preclinical studies, long-term treatment of APP trans-
genic Tg2576 mice with ibuprofen and indomethacin
were effective in reducing the plaque pathology [51,117].
Also, acute treatment with additional NSAIDs, sulindac Journal of Neuroinflammation 2008, 5:25 http://www.jneuroinflammation.com/content/5/1/25
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Table 1: Comparison of the effects of NSAIDs on APP secretases. The decrease in BACE1 was detected under inflammatory 
conditions.
NSAIDs activity α-secretase β-secretase γ-secretase
Ibuprofen PPARγ activator ↑(69)  (70,71) ↓ (70,90) ↓Aβ42/Aβ40 (108)
Indomethacin PPARγ activator NFκB inhibitor ↑ (69)   (71) ↓ (70,90) ↓Aβ42/Aβ40 (108)
Naproxen PPARγ activator ? ↓ (70,90)   Aβ42/Aβ40 (108)
Flurbiprofen NFκB inhibitor ? ? ↓Aβ42/Aβ40 (54,108)
Aspirin COX-1 inhibitor ?   (90)   Aβ42/Aβ40 (108)
Sulindac sulphide COX-1 inhibitor ?   (90) ↓Aβ42/Aβ40 (108)
Celecoxib COX-2 inhibitor ?   (70,90) ↑Aβ42/Aβ40 (56)
Fenofibrate PPARα activator ? ? ↑Aβ42/Aβ40 (56)
Schematic representation of the interactions between inflammatory processes and APP processing Figure 2
Schematic representation of the interactions between inflammatory processes and APP processing. Aβ generation by BACE1 
and γ-secretase induces an inflammatory response, which involves the activation of microglia and astrocytes and the release of 
pro-inflammatory cytokines. This inflammatory response could be enhanced by brain trauma or by PS1 mutations, probably 
also by increased Aβ production. Inflammatory cytokines have been involved in the aggregation of Aβ [121]. Moreover, 
cytokines can affect the expression of secretases and APP, influencing their transcription, translation and/or activation [122]. 
Non-steroidal anti-inflammatory drug treatment could reverse the effect of inflammation on BACE1 transcription, modulate 
the cleavage site of γ-secretase and decrease the secretion of cytokines and the number of microglia and astrocytes. On the 
other hand, α-secretase has been involved in the shedding of certain cytokines, potentiating their activity. See text for further 
details of individual interactions. Numbers on the diagram correspond to the appropriate references in the review.
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sulfide, and flurbiprofen, selectively reduced Aβ42 levels
without changing the concentration of Aβ40 [54,108].
However, other studies did not reproduce these results
[111,118]. In clinical trials some positive effects on cogni-
tive performance of AD patients were observed with
indomethacin and the (R)-enantiomer of flurbiprofen,
while other NSAIDs without Aβ42 reducing activity did
not reveal beneficial effects [107] (see Table 1 for sum-
mary). Although this indicates that it would be relevant to
evaluate Aβ42 lowering NSAIDs in further clinical trails,
recent epidemiological studies revealed that the protective
effect of NSAIDs seems to be independent of the Aβ42
suppressing activity of the NSAID [119,120].
Conclusion
In summary, in this review we have tried to give a perspec-
tive on the wide variety of interactions between inflamma-
tory mediators and APP secretases. On the one hand, pro-
inflammatory cytokines are able to increase the levels
and/or activity of some secretases, such as α-secretase and
BACE1. On the other hand, NSAIDs are able to modulate
the activity of the secretases by regulating their levels in
the case of BACE1, or by directly shifting the cleavage site
of γ-secretase (see Table 1). In addition it now seems that
α-secretase plays a particularly prominent role in ectodo-
main shedding of inflammatory proteins, thus regulating
the activity of cytokines such as TNFα. Bringing all this
together, it is clear that the association between inflamma-
tion and AD, as suggested by the wealth of epidemiologi-
cal, clinical and laboratory data, is based on a series of
complex molecular interactions that we are only just
beginning to understand in detail (Figure 2). The initial
signs are encouraging but further work is needed in this
area to determine whether modification of these interac-
tions can provide a viable therapeutic target for the treat-
ment of AD.
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